Genzyme Corporation

Katherine Jancsics

Seng H Cheng

Andrew Charles Good

John Marshall

Yibin Xiang

Bradford Hirth

Cassandra Celatka

Ronald K Scheule

Markus Metz

Zhong Zhao

Elyse Bourque

Thomas A Natoli

Elina Makino

Oxana Beskrovnaya

Herve Husson

Mario A Cabrera-Salazar

Renato Skerlj

John P Leonard

Renato Tony Skerlj

John Leonard

Andrew Good

Thomas Natoli

The invention relates to inhibitors of glucosylceramide synthase (GCS) of the Formula I: represented by the following structural formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

Glucosylceramide synthase inhibitors

The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. 

Growing community of inventors

Wilmington, MA, United States of America

Katherine Jancsics